Research and Development
- VAL-001 is in clinical phase IIa with recruitment of patients at Skåne University Hospital and Uppsala University Hospital and Norrlands University Hospital in Umeå.
- RESP-1000 and RESP-2000 are available for out-licensing and continued clinical development. The substance series have extensive patent protection. Respiratorius is exploring potential application outside COPD and asthma.
- RESP-3000 is a potential biomarker for cardiovascular PET-imaging. Currently the project is under evaluation by Genovis AB.